Omeros News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.12.13	Omeros' OMS721 Gets Orphan Drug Status From FDA - Quick Facts (RTTNews)
20.11.13	Omeros: FDA Accepts Brand Name Omidria For OMS302 - Quick Facts (RTTNews)
07.11.13	Omeros Announces Positive Data In Phase 1 Trial With OMS721 (RTTNews)
05.11.13	Omeros Reports Positive Data Using OMS721 In MASP-2 Program (RTTNews)
21.10.13	Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros (PR Newswire)
17.10.13	Omeros Corporation Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement (PR Newswire)
17.10.13	Omeros Reports Addl Positive Data For DrugCandidate To Treat Cognitive Disorders (RTTNews)
17.10.13	Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders (PR Newswire)
15.10.13	Upcoming Financial Results Schedules, Clinical Studies and Trials, and New Appointments - Research Report on BioMarin, Alnylam, Aegerion, Omeros, and Tesaro (PR Newswire)
15.10.13	Omeros: FDA Agrees With OMS302 Pediatric Study Plan - Quick Facts (RTTNews)
15.10.13	FDA Agrees with Omeros' Pediatric Study Plan for OMS302 (PR Newswire)
09.10.13	Beating The Street (RTTNews)
09.10.13	Critical Alerts For General Motors, ExOne, Manitowoc, Varian Medical, and Omeros Released By InvestorsObserver (PR Newswire)
08.10.13	Omeros Hires Michael K. Inouye to Lead Commercial Operations (PR Newswire)
07.10.13	Changes in Senior Management, Grants of Orphan Drug Designations, and Updates on Pipeline Development and NDA - Research Report on Vivus, Omeros, Delcath Systems, Achillion, and Zogenix (PR Newswire)
04.10.13	AMRN Faces FDA Panel On Oct.16, Isis Pockets $2Mln, NEOG Effects Stock Split (RTTNews)
03.10.13	Omeros Announces Settlement With Its Insurer - Quick Facts (RTTNews)
02.10.13	US & European Regulators Accept For Review Omeros'OMS302 Marketing Applications (RTTNews)
02.10.13	US and European Regulators Accept for Review OMS302 Marketing Applications (PR Newswire)
01.10.13	ACRX Files Zalviso NDA, BGMD Gets A Booster, UK's NICE Turns Nice To PSDV (RTTNews)
30.09.13	FDA Grants Orphan Drug Designation To Omeros' OMS824 For Huntington's Disease (RTTNews)
30.09.13	FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease (PR Newswire)
26.09.13	Application for Regulatory Approvals, Conferences and Presentations, and Enrollment in Clinical Trials - Research Report on Gilead, Alnylam, Omeros, PTC, and Stemline (PR Newswire)
20.09.13	Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference (PR Newswire)
19.09.13	Omeros Begins Enrollment In Phase 2 Clinical Trial With OMS824 - Quick Facts (RTTNews)
19.09.13	Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824 (PR Newswire)
12.09.13	Omeros Reports Addl. Positive Results From OMS824 Program - Quick Facts (RTTNews)
12.09.13	Omeros Reports Additional Positive Results from OMS824 Program (PR Newswire)
11.09.13	FOLD Cuts A Deal, SNTA On Watch, NanoString Makes Mega Leap, GALT Vaults (RTTNews)
10.09.13	Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency (PR Newswire)
09.09.13	Omeros to Present at the Stifel Healthcare Conference 2013 (PR Newswire)
13.08.13	Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer (PR Newswire)
09.08.13	Omeros Loss Widens - Quick Facts (RTTNews)
09.08.13	Omeros Corporation Reports Second Quarter 2013 Financial Results (PR Newswire)
08.08.13	Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference (PR Newswire)
02.08.13	ATRC, RGEN See Rosy Future, VICL, INCY To Watch Out For, PCRX Down But Not Out (RTTNews)
01.08.13	Omeros Submits New Drug Application to U.S. FDA for OMS302 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Omeros Corp

Aktien Top/Flop

Meistgelesene Nachrichten